抗2型糖尿病药物研究进展  

Research progress on drugs of anti-type 2 diabetes

作　　者：孟艳秋[1] 刘文虎[1] 刘凤鑫[1] 张宇[1] 薛菁[1] 

机构地区：[1]沈阳化工大学,辽宁沈阳110142

出　　处：《现代药物与临床》2013年第3期461-464,共4页Drugs & Clinic

摘　　要：糖尿病是一种慢性代谢疾病,主要表现为高血糖和微血管并发症。糖尿病患者中有90%～95%为2型糖尿病。近年来2型糖尿病的药物研究重心逐渐从传统致病机制的研究转移到新作用靶点、新致病机制的研究。以国内外相关文献为基础,按照作用机制介绍了一些在临床使用的2型糖尿病治疗药物或正在研制的有关药物。预测钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂将成为未来抗2型糖尿病药物的研发热点,为抗2型糖尿病的药物研究指明了新的方向。Diabetes is a chronic metabolic diseases,and the clinical manifestation is mainly hyperglycemia and microvascular complications.90%—95% of diabetic patients are type 2 diabetes.The research emphases of type 2 diabetes drug is shifting from the research aim at traditional pathogenic mechanism transferred to the research focus on new target and new pathogenic mechanism in recent years.This paper based on the relevant literature,in accordance with the mechanism of type 2 diabetes,presented a number of drugs in the clinical use or under development.In these drugs,the SGLT2 inhibitors will be the hot topic of the future anti-diabetic drugs,which is indicated a new direction for the research of anti-diabetic drugs.

关 键 词：2型糖尿病 作用机制 胰高血糖素样肽-1 SGLT2抑制剂 胰岛素 

分 类 号：R977[医药卫生—药品]